Show source-provided references
2. Jellinger, K.A. (2011). Neurodegeneration: The Molecular Pathology of Dementia and Movement Disorders, Wiley Blackwell Publisher. [2nd ed.].
11. Mumtaz, S., Rana, J.N., Choi, E.H., and Han, I. (2022). Microwave Radiation and the Brain: Mechanisms, Current Status, and Future Prospects. Int. J. Mol. Sci., 23.
10.3390/ijms23169288 ↗13. The Understanding of Parkinson’s Disease through Genetics and New Therapies
10.1002/brb3.2577 ↗14. (2023, March 04). Parkinson’s Disease: Genetics, Pathogenesis and Emerging Therapeutics|Hindawi. Available online: https://www.hindawi.com/journals/bmri/si/426914/.
24. Olfactory Neuron Prokineticin-2 as a Potential Target in Parkinson’s Disease
10.1002/ana.26526 ↗26. Oral Health of Parkinson’s Disease Patients: A Case-Control Study
30. Subjective and Objective Halitosis among Patients with Parkinson’s Disease
10.1111/ger.12293 ↗33. Chen, Y.Y., Fan, H.C., Tung, M.C., and Chang, Y.K. (2019). The Association between Parkinson’s Disease and Temporomandibular Disorder. PLoS ONE, 14.
10.1371/journal.pone.0217763 ↗34. Oral Dysbiosis and Inflammation in Parkinson’s Disease
35. Periodontal Inflammatory Disease Is Associated with the Risk of Parkinson’s Disease: A Population-Based Retrospective Matched-Cohort Study
10.7717/peerj.3647 ↗37. Infective Endocarditis and Dental Procedures: Evidence, Pathogenesis, and Prevention
10.2152/jmi.53.189 ↗38. Fiorillo, L., Cervino, G., Laino, L., D’Amico, C., Mauceri, R., Tozum, T.F., Gaeta, M., and Cicciù, M. (2019). Porphyromonas Gingivalis, Periodontal and Systemic Implications: A Systematic Review. Dent. J., 7.
10.3390/dj7040114 ↗39. Franciotti, R., Pignatelli, P., Carrarini, C., Romei, F.M., Mastrippolito, M., Gentile, A., Mancinelli, R., Fulle, S., Piattelli, A., and Onofrj, M. (2021). Exploring the Connection between Porphyromonas Gingivalis and Neurodegenerative Diseases: A Pilot Quantitative Study on the Bacterium Abundance in Oral Cavity and the Amount of Antibodies in Serum. Biomolecules, 11.
10.3390/biom11060845 ↗40. Evaluation of the Association between Periodontitis and Risk of Parkinson’s Disease: A Nationwide Retrospective Cohort Study
10.1038/s41598-021-96147-4 ↗42. Alvarenga, M.O.P., Frazão, D.R., de Matos, I.G., Bittencourt, L.O., Fagundes, N.C.F., Rösing, C.K., Maia, L.C., and Lima, R.R. (2021). Is There Any Association Between Neurodegenerative Diseases and Periodontitis? A Systematic Review. Front. Aging Neurosci., 13.
10.3389/fnagi.2021.651437 ↗43. Neurodegenerative Disorders and Periodontal Disease: Is There a Logical Connection?
10.1159/000449517 ↗44. Auerbacher, M., Gebetsberger, L., Kaisarly, D., Schmidmaier, R., Hickel, R., and Drey, M. (2022). Oral Health in Patients with Neurodegenerative and Cerebrovascular Disease: A Retrospective Study. Disabil. Rehabil.
10.1080/09638288.2022.2088866 ↗45. Rozas, N.S., Tribble, G.D., Jeter, C.B., Machida, C.A., Maier, T.J., and Said-Al-Naief, N. (2021). Oral Factors That Impact the Oral Microbiota in Parkinson’s Disease. Microorganisms, 9.
10.3390/microorganisms9081616 ↗47. Oral Health Disorders in Parkinson’s Disease: More than Meets the Eye
48. van Vuuren, M.J., Nell, T.A., Carr, J.A., Kell, D.B., and Pretorius, E. (2020). Iron Dysregulation and Inflammagens Related to Oral and Gut Health Are Central to the Development of Parkinson’s Disease. Biomolecules, 11.
10.3390/biom11010030 ↗51. Homayun, B., Lin, X., and Choi, H.J. (2019). Challenges and Recent Progress in Oral Drug Delivery Systems for Biopharmaceuticals. Pharmaceutics, 11.
10.3390/pharmaceutics11030129 ↗52. Current Applications of Drug Delivery Nanosystems Associated with Antimicrobial Photodynamic Therapy for Oral Infections
10.1016/j.ijpharm.2020.120078 ↗53. Mercadante, V., Scarpa, E., de Matteis, V., Rizzello, L., and Poma, A. (2021). Engineering Polymeric Nanosystems against Oral Diseases. Molecules, 26.
10.3390/molecules26082229 ↗55. Mucoadhesive Drug Delivery Systems
60. Alpha-Klotho in Parkinson’s Disease: A Perspective on Experimental Evidence and Potential Clinical Implications
10.4103/1673-5374.335820 ↗64. Evaluation of Galantamine Transbuccal Absorption by Reconstituted Human Oral Epithelium and Porcine Tissue as Buccal Mucosa Models: Part I
10.1016/j.ejpb.2008.06.025 ↗65. (2023, January 03). Assessing the Pharmacokinetics, Safety, Tolerability and Efficacy of Continuous Oral Levodopa Via the DopaFuse® Delivery System in Parkinson’s Disease Patients—Full Text View—ClinicalTrials.Gov, Available online: https://clinicaltrials.gov/ct2/show/NCT04778176.
66. Potential Transbuccal Delivery of L-DOPA Methylester Prodrug: Stability in the Environment of the Oral Cavity and Ability to Cross the Mucosal Tissue
10.3109/10717544.2014.987332 ↗69. di Prima, G., Campisi, G., and de Caro, V. (2020). Amorphous Ropinirole-Loaded Mucoadhesive Buccal Film: A Potential Patient-Friendly Tool to Improve Drug Pharmacokinetic Profile and Effectiveness. J. Pers. Med., 10.
10.3390/jpm10040242 ↗71. Buccal Mucosal Irritation Studies of Sublingual Apomorphine Film (APL-130277) in Syrian Golden Hamsters
10.4155/tde-2016-0043 ↗72. Controlled Delivery of Apomorphine Through Buccal Mucosa, Towards a Noninvasive Administration Method in Parkinson’s Disease: A Preclinical Mechanistic Study
10.1016/j.xphs.2020.05.017 ↗73. Prolonged Delivery of Apomorphine Through the Buccal Mucosa, Towards a Noninvasive Sustained Administration Method in Parkinson’s Disease: In Vivo Investigations in Pigs
10.1016/j.xphs.2020.12.010 ↗74. A Potential Tailor-Made Hyaluronic Acid Buccal Delivery System Comprising Rotigotine for Parkinson’s Disease?
10.4155/fmc.15.66 ↗80. Bioerodible Injectable Poly(Ortho Ester) for Tetracycline Controlled Delivery to Periodontal Pockets: Preliminary Trial in Humans
81. (2023, February 05). Dental Management of Parkinson’s Disease: A Case Report—ProQuest. Available online: https://www.proquest.com/openview/69ede58a766cb511b9d77a2100e83242/1?pq-origsite=gscholar&cbl=41679.
82. Oral Function as an Indexing Parameter for Mild Cognitive Impairment in Older Adults
10.1111/ggi.13259 ↗83. Spurthi, S., Sridharan, S., Hosadurga, R., Rao, R.J., Prabhu, S., Pal, P.K., Kamble, N., Rakesh, K., and Kumar, A. (2023). Effectiveness of Oral Hygiene Educational Interventional Programs on Participants with Parkinson’s Disease: A Randomized Controlled Study. Quintessence Int.
84. Improvement of Oral Function and Hygiene in Parkinson’s Disease: A Randomised Controlled Clinical Trial
10.1111/joor.12924 ↗86. Oral Health-Related Quality of Life in Patients with Parkinson’s Disease Wearing Fixed Partial Dentures—A Prospective Study
88. Nicholson, J.S., and Landry, K.S. (2022). Oral Dysbiosis and Neurodegenerative Diseases: Correlations and Potential Causations. Microorganisms, 10.
10.3390/microorganisms10071326 ↗90. Prosthodontic Considerations in Parkinson’s Disease
93. MiRNA in Parkinson’s Disease: From Pathogenesis to Theranostic Approaches
10.1002/jcp.30932 ↗